Anakinra: A safe and effective first-line treatment in systemic onset juvenile idiopathic arthritis (SoJIA)

Rheumatology International

Volumn 32, Issue 11, 2012, Pages 3525-3530

  Hedrich, C M ^a   Bruck, N ^a   Fiebig, B ^a   Gahr, M ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Anakinra; Inflammation; Interleukin 1; Still's disease; Systemic JIA

Indexed keywords

CORTICOSTEROID; PREDNISOLONE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ARTICLE; BODY TEMPERATURE; CHILD; CLINICAL ARTICLE; CORTICOSTEROID THERAPY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; INJECTION SITE INFLAMMATION; INJECTION SITE PRURITUS; JUVENILE RHEUMATOID ARTHRITIS; MALE; MONOTHERAPY; PRESCHOOL CHILD; PRIORITY JOURNAL; RASH; SCHOOL CHILD; SYSTEMIC ONSET JUVENILE IDIOPATHIC ARTHRITIS; TREATMENT DURATION; TREATMENT RESPONSE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; CHILD; CHILD, PRESCHOOL; CYTOKINES; FEMALE; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MALE; TREATMENT OUTCOME;

EID: 84872189654     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-011-2249-4     Document Type: Article

References (22)

1. Moller JC, Paul D, Ganser G, Range U, Gahr M, Kelsch R, Rosen-Wolff A, Hedrich CM (2010) IL10 promoter polymorphisms are associated with systemic onset juvenile idiopathic arthritis (SoJIA). Clin Exp Rheumatol 28(6):912-918
2. Youm JY, Woo JH, Kim TH, Bae SC, Yoo DH (2007) Interleukin-1beta and interleukin-1 receptor antagonist gene polymorphisms in Korean patients with adult-onset Still's disease. Scand J Rheumatol 36(5):390-393
3. De Benedetti F, Martini A (1998) Is systemic juvenile rheumatoid arthritis an interleukin 6 mediated disease J Rheumatol 25(2):203-207
4. De Benedetti F, Ravelli A, Martini A (1997) Cytokines in juvenile rheumatoid arthritis. Curr Opin Rheumatol 9(5):428-433 (Pubitemid 27437941)
5. Pascual V, Allantaz F, Arce E, Punaro M, Banchereau J (2005) Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 201(9):1479-1486 (Pubitemid 40664091)
6. Hedrich CM, Fiebig B, Sallmann S, Bruck N, Hahn G, Roesler J, Roesen-Wolff A, Heubner G, Gahr M (2008) Good response to IL-1beta blockade by anakinra in a 23-year-old CINCA/NOMID patient without mutations in the CIAS1 gene. Cytokine profiles and functional studies. Scand J Rheumatol 37(5):385-389
7. Naumann L, Feist E, Natusch A, Langen S, Krause A, Buttgereit F, Burmester GR (2010) IL1-receptor antagonist anakinra provides long-lasting efficacy in the treatment of refractory adultonset Still's disease. Ann Rheum Dis 69(2):466-467
8. Ohlsson V, Baildam E, Foster H, Jandial S, Pain C, Strike H, Ramanan AV (2008) Anakinra treatment for systemic onset juvenile idiopathic arthritis (SOJIA). Rheumatology (Oxford) 47(4):555-556 (Epub 2008 Mar 5)
9. Gattorno M, Piccini A, Lasiglié D, Tassi S, Brisca G, Carta S, Delfino L, Ferlito F, Pelagatti MA, Caroli F, Buoncompagni A, Viola S, Loy A, Sironi M, Vecchi A, Ravelli A, Martini A, Rubartelli A (2008) The pattern of response to anti-interleukin-1 treatment distinguishes two subsets of patients with systemiconset juvenile idiopathic arthritis. Arthr Rheum 58(5):1505-1515 (Pubitemid 351705940)
10. Lequerré T, Quartier P, Rosellini D, Alaoui F, De Bandt M, Mejjad O, Kone-Paut I, Michel M, Dernis E, Khellaf M, Limal N, -Deslandre C, Fautrel B, Le Loet X, Sibilia J (2008) Société Francophone pour la Rhumatologie et les Maladies Inflammatoires en Pédiatrie (SOFREMIP); Club Rhumatismes et Inflammation (CRI). Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset still disease: preliminary experience in France. Ann Rheum Dis 67(3):302-308 (Pubitemid 351281262)
11. Nigrovic PA, Mannion M, Prince FH, Zeft A, Rabinovich CE, van Rossum MA, Cortis E, Pardeo M, Miettunen PM, Janow G, Birmingham J, Eggebeen A, Janssen E, Shulman AI, Son MB, Hong S, Jones K, Ilowite NT, Cron RQ, Higgins GC (2011) Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthr Rheum 63(2):545-555
12. Quartier P, Taupin P, Bourdeaut F, Lemelle I, Pillet P, Bost M, Sibilia J, Koné-Paut I, Gandon-Laloum S, LeBideau M, Bader-Meunier B, Mouy R, Debré M, Landais P, Prieur AM (2003) Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. Arthr Rheum 48(4): 1093-1101 (Pubitemid 36418252)
13. Beresford MW, Baildam EM (2009) New advances in the management of juvenile idiopathic arthritis-2: the era of biologicals. Arch Dis Child Educ Pract Ed 94(5):151-156
14. Durand M, Troyanov Y, Laflamme P, Gregoire G (2010) Macrophage activation syndrome treated with anakinra. J Rheumatol 37(4):879-880
15. Bruck N, Suttorp M, Kabus M, Heubner G, Gahr M, Pessler F (2010) Rapid and sustained remission of systemic juvenile idiopathic arthritis-Associated macrophage activation syndrome through treatment with anakinra and corticosteroids. J Clin Rheumatol 17:23-27
16. Maakaroun NR, Moanna A, Jacob JT, Albrecht H (2010) Viral infections associated with haemophagocytic syndrome. Rev Med Virol 20(2):93-105
17. Goldbach-Mansky R, Dailey NJ, Canna SW, Gelabert A, Jones J, Rubin BI, Kim HJ, Brewer C, Zalewski C, Wiggs E, Hill S, Turner ML, Karp BI, Aksentijevich I, Pucino F, Penzak SR, Haverkamp MH, Stein L, Adams BS, Moore TL, Fuhlbrigge RC, Shaham B, Jarvis JN, O'Neil K, Vehe RK, Beitz LO, Gardner G, Hannan WP, Warren RW, Horn W, Cole JL, Paul SM, Hawkins PN, Pham TH, Snyder C, Wesley RA, Hoffmann SC, Holland SM, Butman JA, Kastner DL (2006) Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med 355(6):581-592 (Pubitemid 44200651)
18. Frenkel J, Wulffraat NM, Kuis W (2004) Anakinra in mutation negative NOMID/CINCA syndrome. Arthr Rheum 50:3738-3739
19. Frosch M, Roth J (2007) Systemische Verlaufsform (Morbus Still). In: Wagner N, Dannecker G (eds) Padiatrische Rheumatologie, vol 1. Springer, Heidelberg, pp 181-193
20. Frosch M, Metze D, Foell D, Vogl T, Sorg C, Sunderkotter C, Roth J (2005) Early activation of cutaneous vessels and epithelial cells is characteristic of acute systemic onset juvenile idiopathic arthritis. Exp Dermatol 14(4):259-265 (Pubitemid 40485453)
21. Foell D, Wulffraat N, Wedderburn LR, Wittkowski H, Frosch M, Gerss J, Stanevicha V, Mihaylova D, Ferriani V, Tsakalidou FK, Foeldvari I, Cuttica R, Gonzalez B, Ravelli A, Khubchandani R, Oliveira S, Armbrust W, Garay S, Vojinovic J, Norambuena X, Gamir ML, García-Consuegra J, Lepore L, Susic G, Corona F, Dolezalova P, Pistorio A, Martini A, Ruperto N, Roth J (2010) Paediatric rheumatology international trials organization (PRINTO). Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. JAMA 303(13):1266-1273.
22. Erratum in: JAMA. 2010 May 26;303(20):2034